Literature DB >> 33277391

Kinetic Modeling of 18F-(2S,4R)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism.

Varsha Viswanath1, Rong Zhou2, Hsiaoju Lee2, Shihong Li2, Abigail Cragin2, Robert K Doot2, David A Mankoff2, Austin R Pantel2.   

Abstract

The PET radiotracer 18F-(2S,4R)4-fluoroglutamine (18F-Gln) reflects glutamine transport and can be used to infer glutamine metabolism. Mouse xenograft studies have demonstrated that 18F-Gln uptake correlates directly with glutamine pool size and is inversely related to glutamine metabolism through the glutaminase enzyme. To provide a framework for the analysis of 18F-Gln-PET, we have examined 18F-Gln uptake kinetics in mouse models of breast cancer at baseline and after inhibition of glutaminase. We describe results of the preclinical analysis and computer simulations with the goal of model validation and performance assessment in anticipation of human breast cancer patient studies.
Methods: Triple-negative breast cancer and receptor-positive xenografts were implanted in athymic mice. PET mouse imaging was performed at baseline and after treatment with a glutaminase inhibitor or a vehicle solution for 4 mouse groups. Dynamic PET images were obtained for 1 h beginning at the time of intravenous injection of 18F-Gln. Kinetic analysis and computer simulations were performed on representative time-activity curves, testing 1- and 2-compartment models to describe kinetics.
Results: Dynamic imaging for 1 h captured blood and tumor time-activity curves indicative of largely reversible uptake of 18F-Gln in tumors. Consistent with this observation, a 2-compartment model indicated a relatively low estimate of the rate constant of tracer trapping, suggesting that the 1-compartment model is preferable. Logan plot graphical analysis demonstrated late linearity, supporting reversible kinetics and modeling with a single compartment. Analysis of the mouse data and simulations suggests that estimates of glutamine pool size, specifically the distribution volume (VD) for 18F-Gln, were more reliable using the 1-compartment reversible model than the 2-compartment irreversible model. Tumor-to-blood ratios, a more practical potential proxy of VD, correlated well with volume of distribution from single-compartment models and Logan analyses.
Conclusion: Kinetic analysis of dynamic 18F-Gln-PET images demonstrated the ability to measure VD to estimate glutamine pool size, a key indicator of cellular glutamine metabolism, by both a 1-compartment model and Logan analysis. Changes in VD with glutaminase inhibition support the ability to assess response to glutamine metabolism-targeted therapy. Concordance of kinetic measures with tumor-to-blood ratios provides a clinically feasible approach to human imaging.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  animal imaging; 18F-glutamine; kinetic modeling; numeric simulations; triple negative breast cancer

Mesh:

Substances:

Year:  2020        PMID: 33277391      PMCID: PMC8833875          DOI: 10.2967/jnumed.120.250977

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  31 in total

1.  Dynamic PET/CT imaging of 18F-(2S, 4R)4-fluoroglutamine in healthy volunteers and oncological patients.

Authors:  Xiaoxia Xu; Hua Zhu; Fei Liu; Yan Zhang; Jianhua Yang; Lifang Zhang; Qing Xie; Lin Zhu; Nan Li; Hank F Kung; Zhi Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-12       Impact factor: 9.236

Review 2.  From Krebs to clinic: glutamine metabolism to cancer therapy.

Authors:  Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2016-07-29       Impact factor: 60.716

Review 3.  Glutamine addiction: a new therapeutic target in cancer.

Authors:  David R Wise; Craig B Thompson
Journal:  Trends Biochem Sci       Date:  2010-08       Impact factor: 13.807

4.  Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors.

Authors:  Wenchao Qu; Zhihao Zha; Karl Ploessl; Brian P Lieberman; Lin Zhu; David R Wise; Craig B Thompson; Hank F Kung
Journal:  J Am Chem Soc       Date:  2010-12-29       Impact factor: 15.419

5.  18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.

Authors:  Jeffrey Tseng; Lisa K Dunnwald; Erin K Schubert; Jeanne M Link; Satoshi Minoshima; Mark Muzi; David A Mankoff
Journal:  J Nucl Med       Date:  2004-11       Impact factor: 10.057

6.  Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer.

Authors:  Rong Zhou; Puneet Bagga; Kavindra Nath; Hari Hariharan; David A Mankoff; Ravinder Reddy
Journal:  Cancer Res       Date:  2018-08-02       Impact factor: 12.701

Review 7.  Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer.

Authors:  R J DeBerardinis; T Cheng
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

Review 8.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

Authors:  Ralph J DeBerardinis; Julian J Lum; Georgia Hatzivassiliou; Craig B Thompson
Journal:  Cell Metab       Date:  2008-01       Impact factor: 27.287

9.  In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.

Authors:  Mark P S Dunphy; James J Harding; Sriram Venneti; Hanwen Zhang; Eva M Burnazi; Jacqueline Bromberg; Antonio M Omuro; James J Hsieh; Ingo K Mellinghoff; Kevin Staton; Christina Pressl; Bradley J Beattie; Pat B Zanzonico; John F Gerecitano; David P Kelsen; Wolfgang Weber; Serge K Lyashchenko; Hank F Kung; Jason S Lewis
Journal:  Radiology       Date:  2018-01-31       Impact factor: 11.105

10.  Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).

Authors:  Mary M Robinson; Steven J McBryant; Takashi Tsukamoto; Camilo Rojas; Dana V Ferraris; Sean K Hamilton; Jeffrey C Hansen; Norman P Curthoys
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

View more
  9 in total

Review 1.  Metabolic analysis as a driver for discovery, diagnosis, and therapy.

Authors:  Ralph J DeBerardinis; Kayvan R Keshari
Journal:  Cell       Date:  2022-07-14       Impact factor: 66.850

Review 2.  Novel applications of molecular imaging to guide breast cancer therapy.

Authors:  Christine E Edmonds; Sophia R O'Brien; David A Mankoff; Austin R Pantel
Journal:  Cancer Imaging       Date:  2022-06-21       Impact factor: 5.605

3.  Hyperpolarized [5-13C,4,4-2H2,5-15N]-L-glutamine provides a means of annotating in vivo metabolic utilization of glutamine.

Authors:  Roozbeh Eskandari; Nathaniel Kim; Arsen Mamakhanyan; Michelle Saoi; Guannan Zhang; Marjan Berisaj; Kristin L Granlund; Alex J Poot; Justin Cross; Craig B Thompson; Kayvan R Keshari
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-05       Impact factor: 12.779

Review 4.  Analysis of Four-Dimensional Data for Total Body PET Imaging.

Authors:  Varsha Viswanath; Rhea Chitalia; Austin R Pantel; Joel S Karp; David A Mankoff
Journal:  PET Clin       Date:  2021-01

5.  First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer.

Authors:  Allison S Cohen; Joe Grudzinski; Gary T Smith; Todd E Peterson; Jennifer G Whisenant; Tiffany L Hickman; Kristen K Ciombor; Dana Cardin; Cathy Eng; Laura W Goff; Satya Das; Robert J Coffey; Jordan D Berlin; H Charles Manning
Journal:  J Nucl Med       Date:  2021-04-30       Impact factor: 11.082

6.  Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET Images of Ovarian Cancer.

Authors:  Anthony J Young; Austin R Pantel; Varsha Viswanath; Tiffany L Dominguez; Mehran Makvandi; Hsiaoju Lee; Shihong Li; Erin K Schubert; Daniel A Pryma; Michael D Farwell; Robert H Mach; Fiona Simpkins; Lilie L Lin; David A Mankoff; Robert K Doot
Journal:  J Nucl Med       Date:  2021-04-16       Impact factor: 11.082

7.  Comparison of: (2S,4R)-4-[18F]Fluoroglutamine, [11C]Methionine, and 2-Deoxy-2-[18F]Fluoro-D-Glucose and Two Small-Animal PET/CT Systems Imaging Rat Gliomas.

Authors:  Maxwell W G Miner; Heidi Liljenbäck; Jenni Virta; Semi Helin; Olli Eskola; Petri Elo; Jarmo Teuho; Kerttu Seppälä; Vesa Oikonen; Guangli Yang; Andrea Kindler-Röhrborn; Heikki Minn; Xiang-Guo Li; Anne Roivainen
Journal:  Front Oncol       Date:  2021-10-07       Impact factor: 6.244

8.  Exploiting Glutamine Consumption in Atherosclerotic Lesions by Positron Emission Tomography Tracer (2S,4R)-4-18F-Fluoroglutamine.

Authors:  Senthil Palani; Maxwell W G Miner; Jenni Virta; Heidi Liljenbäck; Olli Eskola; Tiit Örd; Aarthi Ravindran; Minna U Kaikkonen; Juhani Knuuti; Xiang-Guo Li; Antti Saraste; Anne Roivainen
Journal:  Front Immunol       Date:  2022-01-25       Impact factor: 8.786

9.  [18F]-(2S,4R)4-Fluoroglutamine PET Imaging of Glutamine Metabolism in Murine Models of Hepatocellular Carcinoma (HCC).

Authors:  Youngho Seo; Miranda C Craig; Stephanie T Murphy; Jinjin Feng; Xin Chen; Mariia Yuneva
Journal:  Mol Imaging       Date:  2022-07-25       Impact factor: 3.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.